• Laminin (925-933): Precision Tools for Cell Migration Resear

  2026-05-24

  Explore the advanced role of Laminin (925-933) in cell adhesion and migration, with scientific context bridging neurodegeneration and metastasis. This in-depth review reveals new assay insights and highlights APExBIO’s unique peptide capabilities.

• Azithromycin: Macrolide Antibiotic Workflows & Resistance An

  2026-05-23

  Azithromycin empowers bacterial infection research with precise, quantifiable workflows—from resistance screening to trypanosomosis animal models. Discover protocol enhancements, troubleshooting strategies, and the latest advances in impurity quantification for high-confidence experimental results.

• ABCC10 Controls cGAMP Export and Radiotherapy Resistance in

  2026-05-22

  This study identifies the ABC transporter ABCC10 as a key mediator of 2'3'-cGAMP export in cancer cells, which attenuates STING-mediated innate immune signaling and promotes resistance to radiotherapy. These findings provide mechanistic insight into how cGAMP efflux modulates the tumor microenvironment and suggest new strategies to sensitize tumors to radiotherapy.

• Naftifine HCl in Translational Antifungal Research: Mechanis

  2026-05-22

  This thought-leadership article explores the mechanistic foundation and strategic applications of Naftifine HCl, an allylamine antifungal agent, in translational research. By connecting its squalene 2,3-epoxidase inhibition to emerging muscle regeneration science, the piece guides research teams in designing advanced workflows, discusses competitive antifungal benchmarks, and sets a visionary agenda for antifungal translational breakthroughs.

• RNAi Screen Reveals Vesicular Transport Targets in SARS-CoV-

  2026-05-21

  Kerr et al. conducted a comprehensive RNA interference screen identifying host vesicular transport factors crucial for SARS-CoV-2 release, notably implicating Rab11a-mediated pathways. Their integrative approach highlights CDK9 inhibition as a promising antiviral strategy and broadens the translational potential of cell cycle and transcriptional control research.

• COX-2 Pathway Modulation in Muscle Ischemia Post-Venom Injur

  2026-05-21

  This study reveals the dual role of the cyclooxygenase-2 (COX-2) pathway in skeletal muscle regeneration after Bothrops asper venom-induced injury. Early inhibition of COX-2 exacerbates ischemia but later enhances angiogenic signaling, offering nuanced insight into timing and targeting of COX-2 inhibition for tissue repair.

• Mubritinib–HSA Interactions: Implications for Drug Bioavaila

  2026-05-20

  This article examines the molecular recognition mechanisms between mubritinib, a mitochondrial electron transport chain inhibitor, and human serum albumin (HSA), as elucidated by recent multispectroscopic and docking studies. The findings clarify how moderate-affinity binding at HSA's Sudlow site I can influence pharmacological properties, with broad implications for drug design, distribution, and translational research.

• Neutrophil Extracellular Trap Formation in CML: TKI Modulati

  2026-05-20

  This study demonstrates that neutrophil extracellular trap (NET) formation is significantly elevated in chronic myeloid leukemia (CML) and is differentially affected by various tyrosine kinase inhibitors (TKIs). The mechanistic insights suggest a potential link between TKI therapy, NET-associated vascular risk, and CML disease biology, providing a new perspective for translational leukemia research.

• Mubritinib–HSA Binding: Impacts on Drug Distribution and Eff

  2026-05-19

  This study provides a molecular-level analysis of mubritinib’s interaction with human serum albumin (HSA), revealing moderate, site-specific binding and functional effects on the carrier protein. These findings inform drug pharmacokinetics and design strategies, with practical implications for optimizing anti-proliferative agent use in cancer research.

• Difloxacin HCl: Mechanistic Powerhouse for Translational Res

  2026-05-19

  This thought-leadership article explores Difloxacin HCl’s dual roles as a quinolone antimicrobial antibiotic and a modulator of multidrug resistance, providing translational researchers with mechanistic insight and actionable protocol guidance. By synthesizing recent cell cycle checkpoint findings and positioning Difloxacin HCl within the evolving landscape of antimicrobial and oncology research, the article offers a roadmap for leveraging this compound in advanced experimental workflows. The discussion is anchored in up-to-date evidence and sets a new standard in scientific biotech content.

• Anlotinib Hydrochloride: Mechanistic Insights for Advanced A

  2026-05-18

  Explore the advanced mechanism and assay optimization potential of Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, with a scientific deep-dive into its selective action and translational research value. Unique mechanistic analysis and protocol guidance differentiate this cornerstone content.

• BRD4 Inhibition Potentiates Ferroptosis via ROS and FSP1 Mod

  2026-05-18

  This study demonstrates that BRD4 inhibitors, such as (+)-JQ1, broadly sensitize diverse cancer cell lines to erastin-induced ferroptosis through increased reactive oxygen species (ROS) and downregulation of FSP1. The findings clarify mechanistic links between epigenetic regulation and ferroptosis, suggesting new therapeutic strategies for targeting FSP1-dependent cancers.

• Translating ROR1 Targeting: Zilovertamab in Cancer Research

  2026-05-17

  Explore mechanistic insights and translational strategies for leveraging Anti-ROR1 Antibody (Zilovertamab) in advanced cancer research workflows, with emphasis on Wnt5a-induced ROR1 signaling inhibition, high-specificity assay design, and the evolving competitive landscape.

• nor-Binaltorphimine dihydrochloride: Selective κ-Opioid Anta

  2026-05-16

  nor-Binaltorphimine dihydrochloride is a highly selective κ-opioid receptor antagonist enabling precise dissection of opioid receptor signaling and pain modulation mechanisms. Its specificity and robust stability make it indispensable in advanced opioid receptor pharmacology research. This article details its verified properties, mechanism, and research applications with rigorous citation.

• Translating HCV NS3 Protease Inhibition: Strategic Insights

  2026-05-15

  This thought-leadership article bridges mechanistic understanding and translational guidance for researchers exploring hepatitis C virus (HCV) therapy, focusing on Asunaprevir (BMS-650032). It offers a deep dive into NS3 protease inhibition, experimental best practices, and the evolving competitive landscape, while referencing both foundational literature and recent chemical biology advances.

15252 records 1/1017 page Next 12345 下5页 Last page